This is a curated selection of articles, which might be of importance for members of the NCRG. Prof. Mollnes regularly screens through newly published articles in order to provide his scholars an update. Therefore, this selection is highly selective, non all-embracing and might omit likewise important articles! 

In March Prof. Mollnes has provided an extensive article selection (see previous post) – and he is following up for April!

1. Complement blockade for TA-TMA: lessons learned from large pediatric cohort treated with eculizumab.
   Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace GH, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit SW, Mizuno K, Warren M, Davies SM.
2. Complement activation in cerebrospinal fluid in clinically isolated syndrome and early stages of relapsing remitting multiple sclerosis.
   Håkansson I, Ernerudh J, Vrethem M, Dahle C, Ekdahl KN.
3. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
   Brodsky RA, Peffault de Latour R, Rottinghaus ST, Röth A, Risitano AM, Weitz IC, Hillmen P, Maciejewski JP, Szer J, Lee JW, Kulasekararaj AG, Volles L, Damokosh AI, Ortiz S, Shafner L, Liu P,
4. Complement component C3 and the TLR co-receptor CD14 are not involved in angiotensin II induced cardiac remodelling.
   Shahini N, Schjalm C, Nilsson PH, Holt MF, Øgaard JDS, Lien E, Ahmed MS, Attramadal H, Aukrust P, Yndestad A, Mollnes TE, Louwe MC.
5. Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency.
   O’Brien ME, Fee L, Browne N, Carroll TP, Meleady P, Henry M, McQuillan K, Murphy MP, Logan M, McCarthy C, McElvaney OJ, Reeves EP, McElvaney NG.
6. Complement related pattern recognition molecules as markers of short-term mortality in intensive care patients.
   Hansen CB, Bayarri-Olmos R, Kristensen MK, Pilely K, Hellemann D, Garred P.
7. CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.
   Zipfel PF, Wiech T, Stea ED, Skerka C.
8. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
   Röth A, Nishimura JI, Nagy Z, Gaal-Weisinger J, Panse JP, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret-Dulphy J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R.
9. Successful simultaneous liver-kidney transplantation for renal failure associated with hereditary complement C3 deficiency.
   Nayagam JS, McGrath S, Montasser M, Delaney M, Cairns TD, Marchbank KJ, Denton H, Yang Y, Sacks SH, Cook HT, Shah S, Heaton N, Pickering MC, Suddle A.
10. Ischemia and Reperfusion Injury in Kidney Transplantation: Relevant Mechanisms in Injury and Repair.
    Nieuwenhuijs-Moeke GJ, Pischke SE, Berger SP, Sanders JSF, Pol RA, Struys MMRF, Ploeg RJ, Leuvenink HGD.
11. C3a receptor antagonist therapy is protective with or without thrombolysis in murine thromboembolic stroke.
    Ahmad S, Pandya C, Kindelin A, Bhatia K, Chaudhary R, Dwivedi AK, Eschbacher JM, Liu Q, Waters MF, Hoda MN, Ducruet AF.
12. Allergen-Induced C5a/C5aR1 Axis Activation in Pulmonary CD11b₊ cDCs Promotes Pulmonary Tolerance through Downregulation of CD40.
    Antoniou K, Ender F, Vollbrandt T, Laumonnier Y, Rathmann F, Pasare C, Singh H, Köhl J.
13. Complement in the Development of Post-Traumatic Epilepsy: Prospects for Drug Repurposing.
    Chen M, Edwards SR, Reutens DC.
14. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Lee JW, Kulasekararaj AG.
15. Increased circulating levels of Factor H-Related Protein 4 are strongly associated with age-related macular degeneration.
    Cipriani V, Lorés-Motta L, He F, Fathalla D, Tilakaratna V, McHarg S, Bayatti N, Acar İE, Hoyng CB, Fauser S, Moore AT, Yates JRW, de Jong EK, Morgan BP, den Hollander AI, Bishop PN, Clark SJ.
16. Increased circulating levels of Factor H-Related Protein 4 are strongly associated with age-related macular degeneration.
    Cipriani V, Lorés-Motta L, He F, Fathalla D, Tilakaratna V, McHarg S, Bayatti N, Acar İE, Hoyng CB, Fauser S, Moore AT, Yates JRW, de Jong EK, Morgan BP, den Hollander AI, Bishop PN, Clark SJ.
17.  C1q/TNF-Related Protein 6 Is a Pattern Recognition Molecule That Recruits Collectin-11 from the Complement System to Ligands.
    Kirketerp-Møller N, Bayarri-Olmos R, Krogfelt KA, Garred P.
18. Production of a bispecific antibody targeting TNF-α and C5a in Pichia pastoris and its therapeutic potential in rheumatoid arthritis.
    Chen J, He Z, Fan Y, Zhou X, Li L, Liu M.
19. A randomized, double-blind, active-controlled, Phase 3 study to evaluate the safety and efficacy of avacopan, a C5a receptor inhibitor, in patients with ANCA-associated vasculitis treated concomitantly with rituximab or cyclophosphamide/ azathioprine.
    Merkel PA, Jayne DR, Wang C, Hillson J, Bekker P.
20. A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients.
    Vo P, Purev E, West KA, McDuffee E, Worthy T, Cook L, Hawks G, Wells B, Shalabi R, Flegel WA, Adams SD, Reger R, Aue G, Tian X, Childs R.
21. Aliskiren as an adjunct therapy for atypical hemolytic uremic syndrome.
    Plasse RA, Nee R, Olson SW.
22. TLR8 and complement C5 induce cytokine release and thrombin activation in human whole blood challenged with Gram-positive bacteria.
    Ehrnström B, Kojen JF, Giambelluca M, Ryan L, Moen SH, Hu Z, Yin H, Mollnes TE, Damås JK, Espevik T, Stenvik J.
23. Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation.
    Lateb M, Ouahmi H, Payré C, Brglez V, Zorzi K, Dolla G, Zaidan M, Boyer-Suavet S, Knebelmann B, Crépin T, Courivaud C, Jourde-Chiche N, Esnault V, Lambeau G, Seitz-Polski B.
24. Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections-A Prospective Observational Study.
    Kristensen MK, Hansen MB, Madsen MB, Hansen CB, Pilely K, Hyldegaard O, Garred P.
25. Changes of coagulation parameters during erythema marginatum in patients with hereditary angioedema.
    Kőhalmi KV, Mező B, Veszeli N, Benedek S, Fehér A, Holdonner Á, Jesenak M, Varga L, Farkas H.
26. Hereditary angioedema in a single family with specific mutations in both plasminogen and SERPING1 genes.
    Bork K, Zibat A, Ferrari DM, Wollnik B, Schön MP, Wulff K, Lippert U.
27. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
    Howard JF Jr, Nowak RJ, Wolfe GI,
28. Effective inhibition of C3a-mediated pro-inflammatory response by a human C3a-specific protein binder.
    Sohn YK, Son S, Choi Y, Hwang DE, Seo HD, Lee JJ, Kim HS
29. Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation.
    Hettmann T, Gillies SD, Kleinschmidt M, Piechotta A, Makioka K, Lemere CA, Schilling S, Rahfeld JU, Lues I.
30. Circulating Ficolin-2 and Ficolin-3 Form Heterocomplexes.
    Jarlhelt I, Pilely K, Clausen JB, Skjoedt MO, Bayarri-Olmos R, Garred P.
31. Complement factor I deficiency: A potentially treatable cause of fulminant cerebral inflammation.
    Altmann T, Torvell M, Owens S, Mitra D, Sheerin NS, Morgan BP, Kavanagh D, Forsyth R.
32. Perioperative Management of Patients With Hereditary Angioedema With Special Considerations for Cardiopulmonary Bypass.
    Tanaka KA, Mondal S, Morita Y, Williams B, Strauss ER, Cicardi M.
33. Neutralizing Complement C5a Protects Mice with Pneumococcal Pulmonary Sepsis.
    Müller-Redetzky H, Kellermann U, Wienhold SM, Gutbier B, Lienau J, Hellwig K, Reppe K, Letsiou E, Tschernig T, Scholz M, Ahnert P, Maasch C, Hoehlig K, Klussmann S, Vater A, Firsching TC, Hoppe J, Suttorp N, Witzenrath M.